CAR-MA Preparation Service

Fig.1 CAR-MA transfection approaches.
(Creative Biolabs)

Chimeric antigen receptor (CAR) T cell therapy has shown promise in hematologic malignancies, but its application to solid tumors has been challenging. Given the unique effector functions of macrophages and their capacity to penetrate tumors, genetically engineered human macrophages with CARs make it possible to produce direct phagocytic activity against tumors. Creative Biolabs is pleased to announce our custom chimeric antigen receptor macrophage (CAR-MA) preparation service.

Virus Packaging Service

Macrophages are highly resistant to genetic engineering with standard vectors such as lentivirus, retrovirus, and adeno-associated viruses (AAV). The vector requires fine-tuning and molecular adjustments to better transfer to macrophages.

• Lentiviral vector: Vpx, an accessory protein, can bind to and counteract lentivirus restriction factor SAMHD1. The use of Vpx-packaged lentiviral particles for transduction of myeloid cells will lead to a restored level of dNTPs, which indicates successful reverse transcription of the lentiviral vector constructs.
• Ad5F35 vector: Macrophages are efficiently transduced by the chimeric-fiber adenoviral vector Ad5F35. Importantly, the transduction with Ad5F35 vector-regardless of CAR expression induces a pro-inflammatory M1 phenotype in the infected macrophages with upregulation of interferon-induced and antigen-presenting machinery genes. Ad5f35 transduced primary human CAR-MA has demonstrated targeted phagocytosis.

CAR-MA Generation

Creative Biolabs provides reliable and available sources of macrophages including induced pluripotent stem cells (iPSC), human monocytic cell line (THP-1), human primary macrophages (CD14+ peripheral blood), murine macrophages (Raw264.7, J774A.1), etc. In general, iPSC-derived macrophages may become an important source of cells for myeloid-based cancer immunotherapy.

Fig. 2 CAR-MA generation.¹

With an experienced expert team, Creative Biolabs offers high-quality CAR-MA preparation services. If you are interested in our services, please feel free to contact us.

Reference

1. Sloas, Christopher, Saar Gill, and Michael Klichinsky. "Engineered CAR-macrophages as adoptive immunotherapies for solid tumors." Frontiers in immunology 12 (2021): 783305. Distributed under Open Access license CC BY 4.0, without modification.